Impact of Growth Hormone on Blastocyst Quality in Older Women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial investigates the effect of growth hormone (GH) supplementation on the euploid rate of blastocysts in women aged 38 and older undergoing preimplantation genetic testing for aneuploidy (PGT-A). Participants will be randomly assigned to receive either GH during ovarian stimulation or standard treatment without GH. The primary outcome measured will be the rate of euploid blastocysts, which are embryos with the correct number of chromosomes. This study aims to determine if GH can improve embryo quality in older women facing infertility.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥38; intended to undergo PGT-A
* BMI in the normal range (18.50-24.0kg/m2)
* Normal semen analysis for the male partner

Exclusion Criteria:

* Endometriosis grade 3 or higher, untreat hydrosalpinx
* Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)
* Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease
* History of endocrine disorder, autoimmune diseases or diagnosed thrombophilia
* History of GH supplementation in the previous IVF treatment or taking other supplementary drugs used during stimulation; patients with absolute or relative contraindications to GH treatment, including active malignancy or history of cancer, diabetic retinopathy, diabetes mellitus, and chronic kidney disease.

Where it's running

• Shanghai JIAI Genetics and IVF Institute
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: XIAOXI SUN, PhD — Shanghai JiAi Genetics & IVF Institute, China
• Study coordinator: Yilun Sui, Md
• Email: 08301010255@fudan.edu.cn
• Phone: 86-13661553127

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Progestin-primed ovarian stimulation with corifollitropin alfa versus standard rFSH/GnRH antagonist (crossover)

  This study will test whether progestin-primed ovarian stimulation using a single-dose corifollitropin alfa improves patient satisfaction and compliance while producing similar ovarian response compared with conventional recombinant FSH plus a GnRH antagonist in women having their first IVF/ICSI cycle for fertility pres

  Recruiting Phase 4 University Hospital, Ghent · Ghent · NCT06175832

• Understanding growth hormone deficiency after a brain injury in adults

  This observational study tests whether growth hormone deficiency affects quality of life and symptoms in adults with traumatic brain injury and whether GH replacement helps after 12 weeks.

  Recruiting University of Calgary · Calgary, Alberta and 1 other locations · NCT07795736

• Belgians and Luxembourgians with childhood GHD: adult outcomes and follow-up

  This study tests how adults who had childhood-onset growth hormone deficiency and were treated with rhGH fare in follow-up and ongoing treatment.

  Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Brussels, Woluwe-saint-lambert · NCT06694506

• Observational study on the effectiveness and safety of SKYTROFA for growth hormone deficiency

  This study is testing how well and safely SKYTROFA works for people with growth hormone deficiency by looking at their experiences during regular treatment.

  Recruiting at 27 sites Ascendis Pharma A/S · Phoenix, Arizona and 26 other locations · NCT05820672

• Long-term safety assessment of lonapegsomatropin in children with growth hormone deficiency

  This study looks at the long-term safety of lonapegsomatropin in children with growth hormone deficiency who are already being treated with it.

  Recruiting at 27 sites Ascendis Pharma A/S · Phoenix, Arizona and 26 other locations · NCT05775523

• Effects of growth hormone and liraglutide on appetite regulation

  This study is testing if growth hormone and liraglutide can change appetite-related hormones in healthy adults and those with growth hormone deficiency to see how they affect weight and energy use.

  Recruiting Phase 4 Columbia University · New York, New York · NCT05681299

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.